Signature BioScience Receives Its Third U.S. Patent for MCS Technology.Business Editors/Health & Medical Writers HAYWARD, Calif.--(BUSINESS WIRE)--March 25, 2002 Signature BioScience, Inc. announced today that the U.S. Patent and Trademark Office has issued another U.S. patent covering aspects of the company's core technology, Multipole Coupling Spectroscopy (MCS), which is a key component of its novel drug discovery platform, WaveScreen(TM). The inventions claimed in this patent -- U.S. Patent No. 6,338,968 -- are related to Signature's basic MCS technology and cover a method for detecting binding of any ligand ligand (lĭg`ənd), charged or uncharged molecule with one or more unshared pairs of electrons that can attach to a central metallic atom or ion to form an aggregate known as a complex ion (see chemical bond). to any antiligand without use of a label by analyzing the dielectric dielectric (dī'ĭlĕk`trĭk), material that does not conduct electricity readily, i.e., an insulator (see insulation). A good dielectric should also have other properties: It must resist breakdown under high voltages; it should not properties of the bound molecular complex. This detection technology is central to Signature's drug discovery business and solidifies the company's proprietary position. Signature's MCS technology uses radio-wave and micro-wave frequencies to detect the physical and biological properties of molecules and cells, such as target drug receptors, and to detect the interaction of two molecules with each other in real time, such as the binding of a test compound to a target drug receptor. Newly issued patent, U.S. Patent No. 6,338,968, is entitled "Method and apparatus for detecting molecular binding events." Signature's patent portfolio relating to relating to relate prep → concernant relating to relate prep → bezüglich +gen, mit Bezug auf +acc MCS consists of five issued patents -- four in the U.S., one in the U.K. -- with more than 30 additional applications currently filed. About Signature BioScience Signature is a detection-based drug discovery company committed to efficiently delivering highly qualified pre-clinical leads for potential treatment of cancer and other diseases. The company is integrating its complementary screening technologies, MCS and Cytection(TM), with chemistries and informatics to create a novel drug discovery platform, WaveScreen(TM), which allows direct examination of a wide range of biologic activities. Signature offers access to WaveScreen on a fee-for-service basis, while internally using the platform to discover drug candidates for out-license to pharmaceutical and biotech partners prior to the clinical development stage. Signature's drug discovery efforts are currently focused on three research-stage programs, two in cancer and one against an infectious disease Infectious disease A pathological condition spread among biological species. Infectious diseases, although varied in their effects, are always associated with viruses, bacteria, fungi, protozoa, multicellular parasites and aberrant proteins known as prions. target, as well as on PC4071, a compound that is being studied in two Phase II trials, for the treatment of ovarian cancer ovarian cancer Malignant tumour of the ovaries. Risk factors include early age of first menstruation (before age 12), late onset of menopause (after age 52), absence of pregnancy, presence of specific genetic mutations, use of fertility drugs, and personal history of breast and soft tissue sarcoma soft tissue sarcoma Oncology A sarcoma that arises in muscle, fat, fibrous tissue, blood vessels, or other supporting tissues. See Sarcoma. Soft tissue sarcoma staging I A . The company is also globally commercializing its MCS-based WaveSpec(TM) instrumentation in collaboration with its partner MDS MDS, n See temporomandibular pain-dysfunction syndrome. MDS 1 Maternal deprivation syndrome, see there 2 Myelodysplastic syndrome, see there Sciex. Signature employs more than 140 biologists, chemists, engineers, computer scientists and support staff in its lab and office facilities in the San Francisco Bay Area “Bay Area” redirects here. For other uses, see Bay Area (disambiguation). The San Francisco Bay Area, colloquially known as the Bay Area or The Bay . Note to Editors: WaveScreen, WaveSpec and Cytection are trademarks of Signature BioScience, Inc. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion